Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 32 Records) |
| Query Trace: Ovarian Neoplasms and BRAF[original query] |
|---|
| The effects of common genetic variants in oncogenes on ovarian cancer survival. Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Sep 14 (18): 5833-9. Quaye Lydia, Gayther Simon A, Ramus Susan J, Di Cioccio Richard A, McGuire Valerie, Hogdall Estrid, Hogdall Claus, Blaakr Jan, Easton Douglas F, Ponder Bruce A J, Jacobs Ian, Kjaer Susanne Kruger, Whittemore Alice S, Pearce Celeste Leigh, Pharoah Paul D P, Song Hongl |
| KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. British journal of cancer 2008 Dec 99 (12): 2020-8. Nakayama N, Nakayama K, Yeasmin S, Ishibashi M, Katagiri A, Iida K, Fukumoto M, Miyazaki |
| Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer. Neoplasia (New York, N.Y.) 2008 Nov 10 (11): 1253-8. Gorringe Kylie L, Choong David Yh, Williams Louise H, Ramakrishna Manasa, Sridhar Anita, Qiu Wen, Bearfoot Jennifer L, Campbell Ian |
| Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer research 2009 May 69 (9): 4036-42. Kuo Kuan-Ting, Guan Bin, Feng Yuanjian, Mao Tsui-Lien, Chen Xu, Jinawath Natini, Wang Yue, Kurman Robert J, Shih Ie-Ming, Wang Tian- |
| Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer. British journal of cancer 2009 Mar 100 (6): 993-1001. Quaye L, Song H, Ramus S J, Gentry-Maharaj A, Høgdall E, DiCioccio R A, McGuire V, Wu A H, Van Den Berg D J, Pike M C, Wozniak E, Doherty J A, Rossing M A, Ness R B, Moysich K B, Høgdall C, Blaakaer J, , Easton D F, Ponder B A J, Jacobs I J, Menon U, Whittemore A S, Krüger-Kjaer S, Pearce C L, Pharoah P D P, Gayther S |
| Improved classification of epithelial ovarian cancer: results of 3 danish cohorts. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2011 Dec 21 (9): 1592-600. Steffensen Karina Dahl, Waldstrøm Marianne, Grove Anni, Lund Bente, Pallisgård Niels, Jakobsen Ande |
| PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Molecular cancer therapeutics 2011 Mar 10 (3): 558-65. Janku Filip, Tsimberidou Apostolia M, Garrido-Laguna Ignacio, Wang Xuemei, Luthra Rajyalakshmi, Hong David S, Naing Aung, Falchook Gerald S, Moroney John W, Piha-Paul Sarina A, Wheler Jennifer J, Moulder Stacy L, Fu Siqing, Kurzrock Razel |
| BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer 2012 Aug . Grisham RN, Iyer G, Garg K, Delair D, Hyman DM, Zhou Q, Iasonos A, Berger MF, Dao F, Spriggs DR, Levine DA, Aghajanian C, Solit DB |
| PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012 Mar 30 (8): 777-82. Janku Filip, Wheler Jennifer J, Westin Shannon N, Moulder Stacy L, Naing Aung, Tsimberidou Apostolia M, Fu Siqing, Falchook Gerald S, Hong David S, Garrido-Laguna Ignacio, Luthra Rajyalakshmi, Lee J Jack, Lu Karen H, Kurzrock Razel |
| TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. Experimental and molecular pathology 2013 Oct 95 (2): 235-41. Rechsteiner Markus, Zimmermann Anne-Katrin, Wild Peter J, Caduff Rosmarie, von Teichman Adriana, Fink Daniel, Moch Holger, Noske Aurel |
| Distinct molecular profiles in Lynch syndrome-associated and sporadic ovarian carcinomas. International journal of cancer. Journal international du cancer 2013 Dec 133 (11): 2596-608. Niskakoski Anni, Kaur Sippy, Renkonen-Sinisalo Laura, Lassus Heini, Järvinen Heikki J, Mecklin Jukka-Pekka, Bützow Ralf, Peltomäki Päi |
| Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma. Virchows Archiv : an international journal of pathology 2014 Aug 465 (2): 193-8. Zannoni Gian Franco, Improta Giuseppina, Chiarello Gaia, Pettinato Angela, Petrillo Marco, Scollo Paolo, Scambia Giovanni, Fraggetta Filip |
| Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. The New England journal of medicine 2015 Aug 373 (8): 726-36. Hyman David M, Puzanov Igor, Subbiah Vivek, Faris Jason E, Chau Ian, Blay Jean-Yves, Wolf Jürgen, Raje Noopur S, Diamond Eli L, Hollebecque Antoine, Gervais Radj, Elez-Fernandez Maria Elena, Italiano Antoine, Hofheinz Ralf-Dieter, Hidalgo Manuel, Chan Emily, Schuler Martin, Lasserre Susan Frances, Makrutzki Martina, Sirzen Florin, Veronese Maria Luisa, Tabernero Josep, Baselga Jo |
| Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. BMC cancer 2015 15 (1): 415. Mackenzie Robertson, Kommoss Stefan, Winterhoff Boris J, Kipp Benjamin R, Garcia Joaquin J, Voss Jesse, Halling Kevin, Karnezis Anthony, Senz Janine, Yang Winnie, Prigge Elena-Sophie, Reuschenbach Miriam, Doeberitz Magnus Von Knebel, Gilks Blake C, Huntsman David G, Bakkum-Gamez Jamie, McAlpine Jessica N, Anglesio Michael |
| A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer. Gynecologic oncology 2016 Apr 141 (1): 108-12. Penson R T, Sales E, Sullivan L, Borger D R, Krasner C N, Goodman A K, Del Carmen M G, Growdon W B, Schorge J O, Boruta D M, Castro C M, Dizon D S, Birrer M |
| Low-grade serous ovarian cancer: A review. Gynecologic oncology 2016 Aug . Kaldawy Anis, Segev Yakir, Lavie Ofer, Auslender Ron, Sopik Victoria, Narod Steven |
| Clonal composition of human ovarian cancer based on copy number analysis reveals a reciprocal relation with oncogenic mutation status. Cancer letters 2017 7 405 22-28. Sakai Kazuko, Ukita Masayo, Schmidt Jeanette, Wu Longyang, De Velasco Marco A, Roter Alan, Jevons Luis, Nishio Kazuto, Mandai Masa |
| EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas. Cancer research 2017 Jun . Etemadmoghadam Dariush, Azar Walid J, Lei Ying, Moujaber Tania, Garsed Dale W, Kennedy Catherine, Fereday Sian, Mitchell Chris, Chiew Yoke-Eng, Hendley Joy, Group Australian Ovarian Cancer Study, Sharma Raghwa, Harnett Paul, Li Jason, Christie Elizabeth L, Patch Ann-Marie, George Joshy, Au-Yeung George, Mir Arnau Gisela, Holloway Timothy P, Semple Timothy, Pearson John V, Waddell Nicola, Grimmond Sean, Köbel Martin, Rizos Helen, Lomakin Ivan, Bowtell David D L, DeFazio An |
| Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing. Genes, chromosomes & cancer 2018 02 57 (2): 51-60. Shibuya Yusuke, Tokunaga Hideki, Saito Sakae, Shimokawa Kazurou, Katsuoka Fumiki, Bin Li, Kojima Kaname, Nagasaki Masao, Yamamoto Masayuki, Yaegashi Nobuo, Yasuda J |
| Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer. Neoplasia (New York, N.Y.) 2019 May 21 (6): 582-590. Van Nieuwenhuysen Els, Busschaert Pieter, Laenen Annouschka, Moerman Philippe, Han Sileny N, Neven Patrick, Lambrechts Diether, Vergote Igna |
| DNA Repair and Ovarian Carcinogenesis: Impact on Risk, Prognosis and Therapy Outcome. Cancers 2020 Jun 12 (7): . Tomasova Kristyna, Cumova Andrea, Seborova Karolina, Horak Josef, Koucka Kamila, Vodickova Ludmila, Vaclavikova Radka, Vodicka Pav |
| Exploring the real-world effect of the SARS-CoV-2 pandemic on the molecular diagnostics for cancer patients and high-risk individuals. Expert review of molecular diagnostics 2020 12 21 (1): 101-107. Cavic Milena, Krivokuca Ana, Boljevic Ivana, Spasic Jelena, Mihajlovic Milica, Pavlovic Marijana, Damjanovic Ana, Radosavljevic Davorin, Jankovic Radmi |
| Therapeutic options for mucinous ovarian carcinoma. Gynecologic oncology 2020 Jan . Gorringe Kylie L, Cheasley Dane, Wakefield Matthew J, Ryland Georgina L, Allan Prue E, Alsop Kathryn, Amarasinghe Kaushalya C, Ananda Sumitra, Bowtell David D L, Christie Michael, Chiew Yoke-Eng, Churchman Michael, DeFazio Anna, Fereday Sian, Gilks C Blake, Gourley Charlie, Hadley Alison M, Hendley Joy, Hunter Sally M, Kaufmann Scott H, Kennedy Catherine J, Köbel Martin, Le Page Cecile, Li Jason, Lupat Richard, McNally Orla M, McAlpine Jessica N, Pyman Jan, Rowley Simone M, Salazar Carolina, Saunders Hugo, Semple Timothy, Stephens Andrew N, Thio Niko, Torres Michelle C, Traficante Nadia, Zethoven Magnus, Antill Yoland C, Campbell Ian G, Scott Clare |
| Spectrum of BRAF Mutations and Gene Rearrangements in Ovarian Serous Carcinoma. JCO precision oncology 2021 5 . Chui M Herman, Chang Jason C, Zhang Yanming, Zehir Ahmet, Schram Alison M, Konner Jason, Drilon Alexander E, Da Cruz Paula Arnaud, Weigelt Britta, Grisham Rachel |
| Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation. Gynecologic oncology reports 2022 3 40 100942. Lima Bárbara, Abreu Miguel Henriques, Sousa Susana, Bartosch Carla, Pereira Deolin |
| BRAF Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition. JCO precision oncology 2022 2 2 1-14. Moujaber Tania, Etemadmoghadam Dariush, Kennedy Catherine J, Chiew Yoke-Eng, Balleine Rosemary L, Saunders Catherine, Wain Gerard V, Gao Bo, Hogg Russell, Srirangan Sivatharsny, Kan Casina, Fereday Sian, Traficante Nadia, , Patch Ann-Marie, Pearson John V, Waddell Nicola, Grimmond Sean M, Dobrovic Alexander, Bowtell David D L, Harnett Paul R, deFazio An |
| Investigating a clinically actionable BRAF mutation for monitoring low-grade serous ovarian cancer: A case report. Case reports in women's health 2022 2 34 e00395. Silva R, Moran B, Das S, Mulligan N, Doughty M, Treacy A, Sheahan K, Kelly C M, Duffy A G, Perry A S, Brennan D |
| Molecular Status of BRAF Mutation in Epithelial Ovarian Cancer: An Analysis of 57 Cases in the Northeast of Iran. Iranian journal of pathology 2023 8 18 (2): 134-139. Amirhossein Jafarian, Masoumeh Jafaripour, Masoumeh Gharib, Maryam Salehi, Nema Mohamadian Roshan, Sare Etemad, Khatoone Mirshekar, Maryam Sheikhi, Masoumeh Heidari, Behnaz Ahmadian, Zahra Khoshnegah, Hossein Ayatollahi, Payam Siyad |
| Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome. Gynecologic oncology 2023 5 174 157-166. John P Thomson, Robert L Hollis, Juliette van Baal, Narthana Ilenkovan, Michael Churchman, Koen van de Vijver, Frederike Dijk, Alison M Meynert, Clare Bartos, Tzyvia Rye, Ian Croy, Patricia Diana, Mignon van Gent, Helen Creedon, Rachel Nirsimloo, Fiona Nussey, Christianne Lok, C Simon Herrington, Charlie Gourl |
| Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma. Scientific reports 2023 5 13 (1): 7681. Robert L Hollis, John P Thomson, Juliette van Baal, Narthana Ilenkovan, Michael Churchman, Koen van de Vijver, Frederike Dijk, Alison M Meynert, Clare Bartos, Tzyvia Rye, Ian Croy, Patricia Diana, Mignon van Gent, Helen Creedon, Rachel Nirsimloo, Christianne Lok, Charlie Gourley, C Simon Herringt |
- Page last reviewed:Feb 1, 2024
- Content source: